Loss of dopamine uptake sites and dopamine D2 receptors in striatonigral degeneration

Brain Research

Volumn 852, Issue 1, 2000, Pages 228-232

  González, Antonio M ^a   Berciano, José ^a   Figols, Javier ^a   Pazos, Angel ^a   Pascual, Julio ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

3H Nemonapride; 3H WIN 35428; Dopamine D2 receptor; Dopamine uptake transporter; Parkinson's disease; Striatonigral degeneration

Indexed keywords

3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; LEVODOPA;

ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUMAN TISSUE; MALE; NERVE DEGENERATION; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL;

AGED; AUTORADIOGRAPHY; BENZAMIDES; CADAVER; CARRIER PROTEINS; COCAINE; CORPUS STRIATUM; DOPAMINE ANTAGONISTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE; PUTAMEN; RECEPTORS, DOPAMINE D2; REFERENCE VALUES; STRIATONIGRAL DEGENERATION;

EID: 0342470608     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02205-2     Document Type: Article

References (17)

1. Antonini A., Leenders K.L., Vontobel P., Maguire R.P., Missimer J., Psylla M., Gunther I. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain. 120:1997;2187-2195.
2. 18F ]dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy Ann. Neurol. 28:1990;547-555.
3. 11C ]raclopride and positron emission tomography Ann. Neurol. 31:1992;184-192.
4. 2 receptors. Ann. Neurol. 34:1993;219-226.
5. 2 sites in Parkinson syndrome of different etiology. Brain Res. 483:1989;30-38.
6. 2 receptor density remains constant in treated Parkinson's disease. Ann. Neurol. 19:1986;487-492.
7. Hughes A.J., Colosino C., Kleedorfer B., Daniel S.E., Lees A.J. The dopaminergic response in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry. 55:1992;1009-1013.
8. Hughes A.J., Daniel S.E., Kilford L., Lees A. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184.
9. Hughes A.J., Daniel S.E., Blankson S., Lees A. A clinicopathological study of 100 cases of Parkinson's disease. Arch. Neurol. 50:1993;140-148.
10. Niznik H.B., Fogel E.F., Fassos F.F., Seeman P. The dopamine transporter is absent in Parkinsonian putamen and reduced in caudate nucleus. J. Neurochem. 56:1991;192-198.
11. Pascual J., Pazos A., del Olmo E., Figols J., Leno C., Berciano J. Presynaptic Parkinsonism in olivopontocerebellar atrophy: clinical, pathological and neurochemical evidence. Ann. Neurol. 30:1991;425-428.
12. 2 receptors in progressive supranuclear palsy: an autoradiographic study. Ann. Neurol. 32:1992;703-707.
13. Pilotte N.S., Sharpe L.G., Kuhar M.J. Withdrawal of repeated intravenous infusions of cocaine persistently reduces binding to dopamine transporters in the nucleus acccumbens of Lewis rats. J. Pharmacol. Exp. Ther. 269:1994;963-969.
14. 123IBZM ]SPECT J. Neurol. Neurosurg. Psychiatry. 57:1994;1047.
15. 123IBZM ] binding predicts dopaminergic responsiveness in patients with Parkinsonism and previous dopaminomimetic therapy Mov. Disord. 12:1997;898-902.
16. 2 receptors in patients with multiple system atrophy Mov. Disord. 12:1997;830.
17. 4 receptors in rat forebrain. NeuroReport. 8:1997;3423-3426.